This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2024 Apr 23;331(16):1417.

doi: 10.1001/jama.2024.0845.

Lepodisiran for Elevated Lipoprotein(a)

Michioki Endo¹, Masahiro Kami²

Affiliations

PMID: 38536182
DOI: 10.1001/jama.2024.0845

Comment

Lepodisiran for Elevated Lipoprotein(a)

Michioki Endo et al. JAMA. 2024.

. 2024 Apr 23;331(16):1417.

doi: 10.1001/jama.2024.0845.

Authors

Michioki Endo¹, Masahiro Kami²

Affiliations

¹ Mitoyo General Hospital, Kanonji City, Japan.
² Medical Governance Research Institute, Minato City, Japan.

PMID: 38536182
DOI: 10.1001/jama.2024.0845

No abstract available

PubMed Disclaimer

Comment in

Lepodisiran for Elevated Lipoprotein(a)-Reply.
Nissen SE, Linnebjerg H, Nicholls SJ. Nissen SE, et al. JAMA. 2024 Apr 23;331(16):1417-1418. doi: 10.1001/jama.2024.0848. JAMA. 2024. PMID: 38536166 No abstract available.

Comment on

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.
Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Nissen SE, et al. JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835. JAMA. 2023. PMID: 37952254 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information